proline and serine rich coiled-coil 1Genealiases: DDA3 · FP3214
Q-omics provides the consensus-scored PSRC1 profile across patient tissues and cancer cell-line models. PSRC1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PSRC1 is differentially expressed in 18, with the highest sampling consensus in HNSC. Additionally, PSRC1 RNA expression shows 18,791 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where PSRC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSRC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSRC1 survival associations across molecular data types. PSRC1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSRC1 RNA expression–survival associations across cancer types. High PSRC1 expression shows unfavorable associations in ACC, KIRP, KIRC, LIHC, MESO and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PSRC1 RNA expression.
This table summarizes PSRC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PSRC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSRC1 shows higher tumor expression in HNSC, COAD, BLCA, LIHC, KIRP and KIRC. The HNSC box plot shows higher PSRC1 RNA expression in tumor versus normal tissue (log2 FC = +1.459, t-test p < 0.001).
This table shows molecular features associated with PSRC1 in patient tissues and cancer cell lines. In patient samples, PSRC1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PSRC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
